https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offers-800m-kelonias-vivo-delivery-know-how
Astellas buying up, pre-clinic.
Astellas bought Xyphos back in 2019 for $120 million upfront with more than $500 million in biobucks available.
Xyphos linking arms with Kelonia in a research and licensing deal worth north of $800 million. Kelonia will receive a $40 million upfront payment for its work and could snag another $35 million should Xyphos buy into the second. The total amount of milestone and contingency payments is close to $800 million.
https://www.fiercebiotech.com/biotech/astellas-owned-xyphos-offer...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
